QLGN News and Press, Qualigen Therapeutics Inc. From 06/08/21

CARLSBAD, Calif., June 08, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral diseases, announced today that according to a preliminary list of additions posted June 4 it...

CARLSBAD, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral diseases, announced today that its CEO and Chairman Michael Poirier will present and partici...

Qualigen (QLGN) appointed Tariq Arshad, MD, MBA to the newly-created position of Senior Vice President, CMO. Most recently, Dr. Arshad was Global Head of Medical Affairs and Clinical Research for Becton Dickinson BioSciences (BDX) in San Jose, California where he led a team of MDs and PhDs dr...

New Position Created to Deepen Clinical Expertise and Advance Pipeline Therapeutic Programs CARLSBAD, Calif., May 19, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing novel therapeutics for t...

Discovery DISCK +24% on definitive agreement with AT&T.Aerpio Pharmaceuticals ARPO +20% on merger deal with Aadi Bioscience.Nuvve Holding Corp. (NVVE) +16%.Aterian (ATER) +13%.Net Element (NETE) +13%.Mind Medicine MNMD +12% on receiving FDA Type C meeting res...

Qualigen Therapeutics (QLGN): Q1 GAAP EPS of -$0.13 beats by $0.01.Revenue of $1.9M (+111.1% Y/Y) beats by $0.7M.As of March 31, 2021, Qualigen Therapeutics had $21.9 million of cash and cash equivalents.Press Release For further details see: Qualigen Therapeutics EPS beats by $0.01, be...

Conference call scheduled for May 18, 2021 at 4:10 p.m. EDT. Revenues Increased 30 Percent to $1.9 Million Compared to $1.5 Million in the Same Quarter of the Previous Year On Track to File an IND in 2H21 for Treating Hospitalized COVID-19 Patients with QN-165 Completed the ...

Qualigen Therapeutics Inc. (NASDAQ:QLGN) traded today at a new 52-week low of $1.77. So far today approximately 1.3 million shares have been exchanged, as compared to an average 30-day volume of 892,000 shares. Qualigen Therapeutics Inc is a biotechnology company focused on the developme...

Shares of Qualigen Therapeutics Inc. (NASDAQ:QLGN) traded today at $1.76, breaking its 52-week low. Approximately 1.3 million shares have changed hands today, as compared to an average 30-day volume of 892,000 shares. Qualigen Therapeutics Inc. (NASDAQ:QLGN) has potential upside of 46.3%...

Qualigen Therapeutics Inc. (NASDAQ:QLGN) traded today at a new 52-week low of $2.02. Approximately 1.3 million shares have changed hands today, as compared to an average 30-day volume of 892,000 shares. In the past 52 weeks, Qualigen Therapeutics Inc. share prices are bracketed by a curr...